Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
-
Authors
-
-
Libert, Diane1
-
Yuan, Constance M2
-
Masih, Katherine E3
-
Galera, Pallavi2
-
Salem, Dalia2
-
Shalabi, Haneen1
-
Yates, Bonnie1
-
Delbrook, Cindy1
-
Shern, Jack F1
-
Fry, Terry J1, 4
-
Khan, Javed3
-
Stetler-Stevenson, Maryalice2
-
Shah, Nirali N5
-
1
Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD, USA.
-
2
Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD, USA.
-
3
Oncogenomics Section, Genetics Branch, CCR, NCI, NIH, Bethesda, MD, USA.
-
4
Division of Human Immunology and Immunotherapy Initiative, Pediatric Hematology/Oncology, Children's Hospital of Colorado, Aurora, CO, USA.
-
5
Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD, USA. [email protected]
- Type
- Published Article
- Journal
-
Leukemia
- Publisher
-
Springer Nature
- Publication Date
-
Nov 01, 2020
- Volume
-
34
- Issue
-
11
- Pages
-
3064–3069
- Identifiers
-
DOI: 10.1038/s41375-020-0760-x
-
PMID: 32103145
- Source
-
Medline
- Language
-
English
- License
-
Unknown
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 11/12/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/32103145
